Wyeth said yesterday that its pharmaceutical division would stop marketing and selling King Pharmaceuticals Inc.’s heart drug Altace next year, ending nearly two years of disputes over their co-promotion partnership.
Wyeth, based in Madison, N.J., with pharmaceutical operations in Collegeville, had agreed in 2000 to work with King, based in Bristol, Tenn., on marketing and promotion of the drug in exchange for a share of its revenue.
But in September 2004, Wyeth sued King, seeking about $8.9 million for an alleged breach of their agreement, Wyeth said in its 2005 annual report. King denied the allegations, and last December it in turn accused Wyeth of defaulting on their agreement.
Most Popular
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
Business Plan Sample
13 Job Interview Mistakes To Avoid
In January, the sides entered discussions on “commercial issues” around Altace, including the default claim, said Wyeth, which vowed to fight in court if agreement could not be reached.
King, in its annual report, said it was …
Read the full article with a Free Trial at MyWire.